Year Created: 1990

Executive 2014-2015
   Dr. Catherine Ross (Hamilton, ON)
Dr. Marciano Reis (Toronto, ON)
Dr. Gaynor Williams (Winnipeg, MB)
Dr. Brian Sheridan (Toronto, ON)
Dr. Louis Wadsworth (Vancouver, BC)
Dr. Carmen Morales (Winnipeg, MB)
Dr. Brian Berry (Victoria, BC)
Dr. Calvino Cheng (Halifax, NS)


  • To create national and regional opportunities for the presentation and discussion of research and development in Hematological Pathology and allied fields.
  • To promote the educational and academic aspects of Hematological Pathology
  • To facilitate the exchange of views and information between members.
  • To foster the highest standards in education, research and practice of Hematological Pathology throughout Canada.
  • To act as an advisory body to the CAP-ACP Executive on matters pertaining to Hematological Pathology. 
  • To operate within the framework of the purposes, objects and aims of the CAP-ACP.

Qualifications for Membership:
Membership in the section shall be available to any member of the Canadian Association of Pathologists regardless of their class of membership provided they have expressed an interest in Hematological Pathology.

2015-2016 Section Report

2015 Hematopathology Symposium - June 22, 2015, Montreal, QC, 0800-1030 

0800-0915 - Diffuse Large B-cell Lymphoma - Leonard Jeffrey Medeirios, The University of Texas MD Anderson Cancer Center 


At the end of this session, participants will be able to:

  • Diagnose morphologic variants and subtypes of diffuse large B-cell lymphoma recognized in the World Health Organization classification.
  • Recognize clinicopathologic and immunophenotypic findings that have prognostic value in patients with diffuse large B-cell lymphoma.
  • Apply results of conventional cytogenetic analysis and fluorescence in situ hybridization to enhance diagnosis of diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma is the most common type of lymphoma worldwide. Although many patients respond well to standard chemotherapy, about 40% of patients relapse or are refractory to primary therapy and have a poor prognosis. It has become clear that a “one size fits all” approach to pathologic diagnosis and therapy is insufficient. Diffuse large B-cell lymphoma is a heterogeneous category of lymphoma as currently defined with highly variable clinical, morphologic, and genetic features. These features can be used for risk stratification and also point to potential therapeutic targets that can be exploited in the design of new therapeutic agents and regimens.

This presentation will begin with the relatively “old fashioned” pathologic definition of this disease. The highly variable clinical, immunophenotypic, cytogenetic, and molecular genetic features of diffuse large B-cell lymphoma and their impact on prognosis or treatment planning will discussed. In addition, various subgroups of diffuse large B-cell lymphoma recognized in the current lymphoma classification system also will be reviewed. It now seems reasonable to conclude that the diagnosis of diffuse large B-cell lymphoma, by itself, is important but insufficient for patient care. Statements must be made regarding tumor biology that will either be essential for risk stratification or will highlight potential targets for which currently therapeutic drugs can be used or for which newer agents in development may be used if the patient experiences relapse.

This session will be of value to pathologists, pathologists-in-training, pathology assistants, and others involved in the care of patients with diffuse large B-cell lymphoma. 

0915-1030 - Lymphoma Classification: The Importance of Getting it Right – Clinical Perspective
Ronan Foley, Hamilton Health Sciences, McMaster University 


At the end of this session, participants will be able to:

  • Know how accurate diagnosis has important consequences on treatment options for patients.
  • Know newer therapeutic approaches in the treatment of T-cell lymphomas based on diagnosis.
  • Know areas of uncertainty, emerging improvements in treatment options for patients with B-cell lymphomas.

As a hematologic oncologist, the clinician’s perspective on pathologic diagnosis of malignant hematologic neoplasms is presented. Emphasis on some of the newer treatment options and pathways as well as areas of uncertainty in treatment algorithms will be discussed.

2014 Hematopathology Symposium - July 14, 2014, Toronto, ON

  • Making Sense of Molecular Mayhem in Myeloid Malignancies
    - Adam Bagg, Hospital of the University of Pennsylvania, Philadelphia, USA
  • The Diagnosis and Classification of Myeloid Neoplasms
    - Robert P. Hasserjan, Massachusetts General Hospital, Harvard Cancer Center, Boston, USA


Specialty Training Requirements in Hematological Pathology


- Updated March 2016 -